Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
May 2018, Vol 8, No 5
Blincyto Approved for Patients with B-Cell ALL and Minimal Residual Disease
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Adcetris Approved as Initial Treatment for Stage III or IV Classical Hodgkin Lymphoma
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Rubraca Approved as Maintenance Treatment for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Survivorship Guidelines Present Challenges in Primary Care
By
Meg Barbor, MPH
Survivorship
May 2018, Vol 8, No 5
Read More ›
Maintaining Work and Productivity a Priority for Cancer Survivors
By
Meg Barbor, MPH
Survivorship
May 2018, Vol 8, No 5
Read More ›
Tagrisso Now Approved as First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutations
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Cabozantinib Active as First-Line Treatment of Differentiated Thyroid Cancer
By
Corbin Davis
2018 Head and Neck Cancers Symposium
,
ASTRO Highlights
May 2018, Vol 8, No 5
Read More ›
Page 2 of 2
1
2